The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by
other antineoplastic agents having similar adverse effects.
Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe
myelosuppression following the administration of CAMPTOSAR. The concurrent administration of CAMPTOSAR with
irradiation has not been adequately studied and is not recommended.
Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of
dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect. However, serious
opportunistic infections have not been observed, and no complications have specifically been attributed to
Hyperglycemia has also been reported in patients receiving CAMPTOSAR. Usually, this has been observed in patients
with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR. It is
probable that dexamethasone, given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.
The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when
prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days
(1.3%, 1/80 patients). The 8.5% incidence of akathisia, however, is within the range reported for use of
prochlorperazine when given as a premedication for other chemotherapies.
It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of
diarrhea, but this has not been studied.
In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the
physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active
vomiting or diarrhea.
Drug-Laboratory Test Interactions
There are no known interactions between CAMPTOSAR and laboratory tests.